title: Novel melanoma therapies and their side effects.
abstract: In the last few years, melanoma treatment has been revolutionized by the development of immune checkpoint-blocking antibodies or immune checkpoint inhibitors including ipilimumab, vemurafenib, dabrafenib, trametinib, nivolumab, and pembrolizumab. Although they have shown promising results, they also have caused multiple adverse events (AEs), particularly immune-related AEs (irAEs). Specialists should be familiar with these AEs.
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: Noelani
authors.initials: N
authors.lastname: González
authors.affiliation: Icahn School of Medicine at Mount Sinai and Mount Sinai Beth Israel, New York, New York, USA.
authors.forename: Désirée
authors.initials: D
authors.lastname: Ratner
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy / Q000209:etiology; D003875:Drug Eruptions / Q000209:etiology; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D000072659:Hypophysitis / Q000139:chemically induced / Q000188:drug therapy; D007037:Hypothyroidism / Q000139:chemically induced / Q000188:drug therapy; D007093:Imidazoles / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007211:Indoles / Q000009:adverse effects; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000627:therapeutic use; D000077594:Nivolumab; D010091:Oximes / Q000009:adverse effects; D011728:Pyridones / Q000009:adverse effects; D011744:Pyrimidinones / Q000009:adverse effects; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects; D016463:Sweet Syndrome / Q000139:chemically induced; D013971:Thyrotoxicosis / Q000139:chemically induced / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000077484:Vemurafenib; D014820:Vitiligo / Q000139:chemically induced
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007093:Imidazoles; D007166:Immunosuppressive Agents; D007211:Indoles; D000074324:Ipilimumab; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D000077484:Vemurafenib; D000077594:Nivolumab; C560077:trametinib; C582435:pembrolizumab; D009173:Mycophenolic Acid; C561627:dabrafenib